Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc.AUPH · Entity 4463 | Director · Chief Executive Officer · 10% owner | May 29, 2026 | June 03, 2026 |
| Bio Green Med Solution, Inc.CYCC · Entity 8225 | 10% owner | February 23, 2017 | February 27, 2017 |
| Boundless Bio, Inc.BOLD · Entity 7063 | 10% owner | August 26, 2026 | August 28, 2026 |
| Fulcrum Therapeutics, Inc.FULC · Entity 5969 | 10% owner | July 16, 2026 | July 21, 2026 |
| Jounce Therapeutics, Inc.JNCE · Entity 15754 | Director · 10% owner | May 03, 2023 | May 05, 2023 |
| Odonate Therapeutics, Inc.ODT · Entity 132524 | Director · Chief Executive Officer · 10% owner | November 17, 2021 | November 19, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aurinia Pharmaceuticals Inc.
Report date May 29, 2026 · Filed June 03, 2026
Jointly reported with TANG CAPITAL MANAGEMENT LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | IndirectBy LP | 13,044,106 |
Last balance in matching sequence
After 2026-06-02 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-05-29 · Purchase · Acquired 2,299 · Balance 12,231,799 F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 2 · 2026-05-29 · Purchase · Acquired 262,682 · Balance 12,494,481 F3: These shares were purchased in multiple transactions ranging from $15.05 to $15.37. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 3 · 2026-06-01 · Purchase · Acquired 343,521 · Balance 12,838,002 F4: These shares were purchased in multiple transactions ranging from $14.97 to $15.50. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 4 · 2026-06-01 · Purchase · Acquired 99 · Balance 12,838,101 F5: These shares were purchased at $15.34. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Row 5 · 2026-06-02 · Purchase · Acquired 206,005 · Balance 13,044,106 F6: These shares were purchased in multiple transactions ranging from $15.00 to $15.40. F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). |
| Short Put Options (potential obligation to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.00 · Expires 2027-01-15 | IndirectBy LP | 10,000 |
Reported balance
After 2026-06-02 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-06-02 · Other · Acquired 10,000 · Balance 10,000 F7: Each put option is exercisable only at the option of the counterparty through the expiration date of the put option. F8: Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6.
F2: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds").
F3: These shares were purchased in multiple transactions ranging from $15.05 to $15.37.
F4: These shares were purchased in multiple transactions ranging from $14.97 to $15.50.
F5: These shares were purchased at $15.34.
F6: These shares were purchased in multiple transactions ranging from $15.00 to $15.40.
F7: Each put option is exercisable only at the option of the counterparty through the expiration date of the put option.
F8: Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027.
Bio Green Med Solution, Inc.
Report date February 23, 2017 · Filed February 27, 2017
Jointly reported with TANG CAPITAL MANAGEMENT LLC, TANG CAPITAL PARTNERS LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 559,900 |
Reported balance
After 2017-02-23 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-02-23 · Purchase · Acquired 134,200 · Balance 559,900 F1: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was executed in multiple trades at prices ranging from $4.09 to $4.50. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin C. Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang disclaims beneficial ownership of the securities, except to the extent of his pecuniary interest therein.
Boundless Bio, Inc.
Report date August 26, 2026 · Filed August 28, 2026
Jointly reported with TANG CAPITAL MANAGEMENT LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 2,840,635 |
Reported balance
After 2026-08-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2026-08-26 · Sale · Disposed 18,300 · Balance 2,840,635 F1: The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70. F2: The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2. F3: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70.
F2: The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2.
F3: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
Fulcrum Therapeutics, Inc.
Report date July 16, 2026 · Filed July 21, 2026
Jointly reported with TANG CAPITAL MANAGEMENT LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 7,080,945 |
Last balance in matching sequence
After 2026-07-17 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-16 · Purchase · Acquired 116,671 · Balance 7,030,000 F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3. F2: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Row 2 · 2026-07-17 · Purchase · Acquired 50,945 · Balance 7,080,945 F3: These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55. F2: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3.
F2: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV.
F3: These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 05, 2023
Jointly reported with TANG CAPITAL MANAGEMENT LLC, TANG CAPITAL PARTNERS LP
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2023-05-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-05-03 · Other · Disposed 5,300,087 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01. F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
| Common StockSEC Table I · non-derivative | IndirectBy LP | 10,000 |
Reported balance
After 2023-05-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2023-05-03 · Other · Acquired 10,000 · Balance 10,000 F4: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs. F5: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of March 26, 2023, by and among the Issuer, Concentra Biosciences, LLC, ("Concentra"), and Concentra Merger Sub, Inc., a wholly-owned subsidiary of Concentra ("Merger Sub"), to which Concentra completed a tender offer (the "Offer") for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.85 per Share (the "Cash Consideration") plus one non-transferable contractual contingent value right per Share (each, a "CVR," and each CVR together with the Cash Consideration, the "Offer Price"). From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $73,118.01.
F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
F4: On May 3, 2023, the Offer expired and Merger Sub accepted for purchase a total of 36,367,727 shares tendered and not withdrawn, representing approximately 69.0926% of the total shares of the Issuer issued and outstanding. Following the expiration of the Offer, Merger Sub merged with and into the Issuer on May 3, 2023, pursuant to Section 251(h) of the Delaware General Corporation Law, and, among other things, each share of common stock of Merger Sub issued and outstanding immediately before the Effective Time automatically converted into and became one validly issued, fully paid and non-assessable share of common stock, par value $0.0001 per share, of the Issuer (representing 10,000 shares in the aggregate), with the Issuer surviving as a wholly owned subsidiary of Concentra. As a result of the Offer and the Merger, Concentra acquired a total of 10,000 shares of Common Stock in exchange for $97,377,034.75 in cash and 60,142,813 CVRs.
F5: The shares are beneficially owned by Concentra. Concentra is wholly owned by TCP. Kevin Tang is the sole manager of TCM, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by Concentra.
Odonate Therapeutics, Inc.
Report date November 17, 2021 · Filed November 19, 2021
Jointly reported with TANG CAPITAL PARTNERS LP, TANG CAPITAL MANAGEMENT LLC, Hearne Michael S
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 12,767,435 |
Last balance in matching sequence
After 2021-11-19 transaction · row 8
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
8 source rowsRow 1 · 2021-11-17 · Sale · Disposed 468,849 · Balance 15,045,717 F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-17 · Sale · Disposed 31,151 · Balance 15,014,566 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-17 · Sale · Disposed 500,000 · Balance 14,514,566 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-17 · Sale · Disposed 287,577 · Balance 14,226,989 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-18 · Sale · Disposed 212,423 · Balance 14,014,566 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-18 · Sale · Disposed 500,000 · Balance 13,514,566 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-18 · Sale · Disposed 381,842 · Balance 13,132,724 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. Row 8 · 2021-11-19 · Sale · Disposed 365,289 · Balance 12,767,435 F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985. F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.01 to $3.01. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 9 herein.
F2: The securities are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. The shares reported as beneficially owned by TCP include a total of 154,285 shares of common stock that are held of record by Odonate Holdings, LLC ("Holdings"). Holdings has granted a proxy to TCP giving TCP the sole authority to vote such shares. Michael Hearne is the Chief Financial Officer of Odonate Therapeutics, Inc., as well as Chief Financial Officer of TCM. Mr. Tang and Mr. Hearne each have a pecuniary interest in a portion of the shares beneficially held by TCP.
F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.99 to $2.005.
F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.95 to $2.07.
F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $2.10 to $2.33.
F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.91 to $2.16.
F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.99.
F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $2.001.
F9: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.985.
Past disclosures · reporting ended (6)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aptevo Therapeutics Inc.
Report date November 23, 2021 · Filed November 26, 2021
Jointly reported with TANG CAPITAL MANAGEMENT LLC, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2021-11-26. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Last balance in matching sequence
After 2021-11-23 transaction · row 7
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
7 source rowsRow 1 · 2021-11-23 · Sale · Disposed 161,336 · Balance 760,000 F1: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 2 · 2021-11-23 · Sale · Disposed 124,509 · Balance 635,491 F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 3 · 2021-11-23 · Sale · Disposed 75,491 · Balance 560,000 F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 4 · 2021-11-23 · Sale · Disposed 149,111 · Balance 410,889 F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 5 · 2021-11-23 · Sale · Disposed 50,889 · Balance 360,000 F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 6 · 2021-11-23 · Sale · Disposed 200,000 · Balance 160,000 F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. Row 7 · 2021-11-23 · Sale · Disposed 160,000 · Balance 0 F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: The prices reported in Column 4 are weighted average prices. These shares were sold in multiple transactions at prices ranging from $13.29 to $13.77. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC Staff, upon request, full information regarding the number of shares sold at each price within the ranges set forth in footnotes 1 and 3 through 8 herein.
F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP.
F3: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.97 to $12.90.
F4: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $11.59 to $11.89.
F5: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.74 to $11.67.
F6: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $10.31 to $10.64.
F7: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.59 to $10.34.
F8: The prices reported in Column 4 are weighted-average prices. These shares were sold in multiple transactions at prices ranging from $9.50 to $10.20.
HERON THERAPEUTICS, INC. /DE/
Report date December 31, 2020 · Filed February 16, 2021
Section 16 reporting ended · disclosed 2021-02-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2020-01-06 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-01-06 · Gift · Disposed 1,600,000 · Balance 0 F1: The gifted securities were held by Tang Capital Partners, LP and were donated to a charitable organization. F2: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. |
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2020-01-07 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2020-01-07 · Gift · Disposed 520,299 · Balance 0 F1: The gifted securities were held by Tang Capital Partners, LP and were donated to a charitable organization. F2: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP. |
| Common StockSEC Table I · non-derivative | IndirectAs Trustee | 3,445 |
Reported balance
Holding disclosure · report date 2020-12-31 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,445 F3: The securities are held by Kevin Tang as custodian for his minor children. |
Filing footnotes · ownership attribution and instrument terms
F1: The gifted securities were held by Tang Capital Partners, LP and were donated to a charitable organization.
F2: The securities were held by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in a portion of the shares beneficially held by TCP.
F3: The securities are held by Kevin Tang as custodian for his minor children.
LA JOLLA PHARMACEUTICAL CO
Report date August 22, 2022 · Filed August 24, 2022
Section 16 reporting ended · disclosed 2022-08-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBY LP | 0 |
Reported balance
After 2022-08-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2022-08-22 · Other · Disposed 9,607,934 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.20 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.69 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.24 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.10 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-08-22 · Disposition to issuer · Disposed 10,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.99 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.93 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2022-08-22 · Disposition to issuer · Disposed 12,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.53 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.81 | Direct | 0 |
Reported balance
After 2022-08-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2022-08-22 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: This transaction represents the voluntary forfeiture of 30,000 unvested stock options for the Reporting Person on August 22, 2022. |
| Series C-1(2) Convertible Preferred StockSEC Table II · derivative / convertible security | IndirectBY LP | 0 |
Reported balance
After 2022-08-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2022-08-22 · Other · Disposed 3,519.315 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of July 10, 2022, by and among the Issuer, Innoviva, Inc., a Delaware corporation ("Parent"), and Innoviva Acquisition Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of the Parent ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of the Issuer, $0.0001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer (the "Merger") effective as of August 22, 2022 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $6.23 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to the excess, if any, of the Offer Price over the exercise price payable per Share with respect to such Issuer Stock Option.
F4: This transaction represents the voluntary forfeiture of 30,000 unvested stock options for the Reporting Person on August 22, 2022.
F5: Pursuant to the Merger Agreement, at the Effective Time, each share of Series C-12 Convertible Preferred Stock was converted into the right to receive an amount in cash equal to 1,724.04 times the Offer Price.
Rain Oncology Inc.
Report date January 26, 2024 · Filed February 02, 2024
Jointly reported with TANG CAPITAL MANAGEMENT LLC, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2024-02-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2024-01-26 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2024-01-26 · Other · Disposed 3,850,513 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. ("Parent"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24. F3: The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share. F4: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 13, 2023, by and among the Issuer, Pathos AI, Inc. ("Parent"), and WK Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, to which Parent completed a tender offer for shares of common stock of the Issuer, $0.001 par value per share (each, a "Share"), and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $1.16 per Share plus one contingent value right for potential cash payments of up to approximately $0.17 per Share. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: The Reporting Person has delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $18,729.24.
F3: The Reporting Persons received the following in exchange for each Share tendered in connection with the Merger: $1.16 in cash per Share and one contingent value right for potential cash payments of up to approximately $0.17 per Share.
F4: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
Singular Genomics Systems, Inc.
Report date February 21, 2025 · Filed February 28, 2025
Jointly reported with TANG CAPITAL MANAGEMENT LLC, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2025-02-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2025-02-21 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2025-02-21 · Disposition to issuer · Disposed 372,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings. F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of December 22, 2024, by and among Singular Genomics Systems, Inc. (the "Issuer"), Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein, all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings.
F2: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
TCR2 THERAPEUTICS INC.
Report date June 01, 2023 · Filed February 14, 2024
Jointly reported with TANG CAPITAL MANAGEMENT LLC, TANG CAPITAL PARTNERS LP
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy LP | 0 |
Reported balance
After 2023-06-01 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2023-06-01 · Other · Disposed 4,394,800 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent. F2: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger. F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of March 5, 2023, by and among TCR2 Therapeutics, Inc. (the "Issuer"), Adaptimmune Therapeutics plc ("Parent"), and CM Merger Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent ("Merger Sub"), as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated April 5, 2023, by and among the Issuer, Parent, and Merger Sub, to which Merger Sub merged with and into the Issuer (the "Merger") with the Issuer surviving the Merger as an indirect wholly-owned subsidiary of Parent effective as of June 1, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive 1.5117 American Depository Shares of Parent ("Parent ADS"), representing six ordinary shares of Parent.
F2: The Reporting Persons received 1.5117 Parent ADSs in exchange for each Share cancelled in connection with the Merger.
F3: The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2026 Filed Aug 28, 2026 20:16 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | SaleCommon Stock | 18,300 | $2.97 | $54,351.00 |
DisclosureSEC source: 0001178579-26-000018 · form4-08282026_080804.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,840,635 F1 · kind: The Reporting Persons have delivered to the Issuer the full amount of the disgorgeable profit arising the sale reported herein, in the amount of $10,046.70. F2 · price: The price reported herein is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $3.03. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares sold at each price within the range set forth in Footnote 2. F3 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 887,715 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 642,589 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 21, 2026 Filed Jul 21, 2026 23:38 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 2,975 | $2.44 | $7,259.00 |
DisclosureSEC source: 0001178579-26-000017 · form4-07212026_110753.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,858,935 F1 · price: The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 23:38 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 1,623 | $2.44 | $3,960.12 |
DisclosureSEC source: 0001178579-26-000017 · form4-07212026_110753.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,855,960 F1 · price: The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 01:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 50,945 | $3.52 | $179,326.40 |
DisclosureSEC source: 0001178579-26-000016 · form4-07212026_010750.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 7,080,945 F3 · price: These shares were purchased in multiple transactions at prices ranging from $3.46 to $3.55. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 17, 2026 Filed Jul 21, 2026 23:38 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 265 | $2.44 | $646.60 |
DisclosureSEC source: 0001178579-26-000017 · form4-07212026_110753.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,854,337 F1 · price: The prices reported are weighted-average prices. These shares were all purchased at $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnote 1. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 655,170 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 893,434 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 655,161 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 655,170 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 16, 2026 Filed Jul 17, 2026 00:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 18,491 | $2.44 | $45,118.04 |
DisclosureSEC source: 0001178579-26-000015 · form4-07172026_120745.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,854,072 F4 · price: These shares were purchased in multiple transactions at prices ranging from $2.43 to $2.44. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 654,055 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 891,914 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 654,048 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 654,055 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 16, 2026 Filed Jul 21, 2026 01:10 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 116,671 | $3.56 | $415,348.76 |
DisclosureSEC source: 0001178579-26-000016 · form4-07212026_010750.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 7,030,000 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 1,668,554 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,212,803 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,668,539 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,531,049 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 15, 2026 Filed Jul 15, 2026 23:50 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 107,377 | $3.56 | $382,262.12 |
DisclosureSEC source: 0001178579-26-000014 · form4-07152026_110717.xml · nonDerivative · entry 4 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,913,329 F5 · price: These shares were purchased in multiple transactions at prices ranging from $3.50 to $3.60. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 1,630,142 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 15, 2026 Filed Jul 17, 2026 00:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 1,600 | $2.44 | $3,904.00 |
DisclosureSEC source: 0001178579-26-000015 · form4-07172026_120745.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,835,581 F3 · price: These shares were all purchased at $2.44. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 654,055 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 891,914 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 654,048 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 654,055 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 23:50 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 75,952 | $3.58 | $271,908.16 |
DisclosureSEC source: 0001178579-26-000014 · form4-07152026_110717.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,805,952 F4 · price: These shares were purchased in multiple transactions at prices ranging from $3.53 to $3.60. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 1,630,142 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 14, 2026 Filed Jul 15, 2026 23:50 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 53,651 | $3.56 | $190,997.56 |
DisclosureSEC source: 0001178579-26-000014 · form4-07152026_110717.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,730,000 F3 · price: These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.60. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 1,630,142 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 14, 2026 Filed Jul 17, 2026 00:10 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 43,878 | $2.43 | $106,623.54 |
DisclosureSEC source: 0001178579-26-000015 · form4-07172026_120745.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,833,981 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.41 to $2.44. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 4. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 654,055 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 891,914 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 654,048 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 654,055 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 13, 2026 Filed Jul 13, 2026 23:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 48,211 | $2.42 | $116,670.62 |
DisclosureSEC source: 0001178579-26-000011 · form4-07132026_110705.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,790,103 F4 · price: These shares were purchased in multiple transactions at prices ranging from $2.35 to $2.44. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 639,395 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 871,923 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 639,390 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 639,395 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 13, 2026 Filed Jul 15, 2026 23:50 UTC | Fulcrum Therapeutics, Inc. FULC · Entity 5969 | PurchaseCommon Stock | 12,966 | $3.54 | $45,899.64 |
DisclosureSEC source: 0001178579-26-000014 · form4-07152026_110717.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 6,676,349 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $3.54 to $3.55. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 5. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 1,630,142 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 2,160,423 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 1,630,127 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 1,492,637 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 10, 2026 Filed Jul 13, 2026 23:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 43,367 | $2.43 | $105,381.81 |
DisclosureSEC source: 0001178579-26-000011 · form4-07132026_110705.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,741,892 F3 · price: These shares were purchased in multiple transactions at prices ranging from $2.38 to $2.48. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 639,395 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 871,923 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 639,390 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 639,395 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 09, 2026 Filed Jul 13, 2026 23:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 7 | $2.48 | $17.36 |
DisclosureSEC source: 0001178579-26-000011 · form4-07132026_110705.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 2,698,525 F1 · price: The prices reported are weighted-average prices. These shares were all purchased at $2.48. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 4. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 639,395 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 871,923 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 639,390 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 639,395 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 08, 2026 Filed Jul 9, 2026 00:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 14,338 | $2.46 | $35,271.48 |
DisclosureSEC source: 0001178579-26-000010 · form4-07092026_120702.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,698,518 F4 · price: These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.48. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 618,407 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 843,301 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 618,403 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 618,407 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 00:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 15,810 | $2.48 | $39,208.80 |
DisclosureSEC source: 0001178579-26-000010 · form4-07092026_120702.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,684,180 F3 · price: These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.50. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 618,407 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 843,301 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 618,403 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 618,407 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 06, 2026 Filed Jul 9, 2026 00:06 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 27,062 | $2.49 | $67,384.38 |
DisclosureSEC source: 0001178579-26-000010 · form4-07092026_120702.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,668,370 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 4. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 618,407 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 843,301 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 618,403 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 618,407 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 23:45 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 9,821 | $2.49 | $24,454.29 |
DisclosureSEC source: 0001178579-26-000009 · form4-07022026_110743.xml · nonDerivative · entry 4 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,641,308 F5 · price: These shares were purchased in multiple transactions at prices ranging from $2.47 to $2.50. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 605,296 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 23:45 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 71,612 | $2.49 | $178,313.88 |
DisclosureSEC source: 0001178579-26-000009 · form4-07022026_110743.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,631,487 F4 · price: These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.50. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 605,296 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:45 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 100 | $2.50 | $250.00 |
DisclosureSEC source: 0001178579-26-000009 · form4-07022026_110743.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,559,875 F3 · price: These shares were all purchased at $2.50. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 605,296 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 23:45 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 25,930 | $2.54 | $65,862.20 |
DisclosureSEC source: 0001178579-26-000009 · form4-07022026_110743.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,559,775 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.49 to $2.60. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 5. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 605,296 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 825,422 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 605,294 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 605,296 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 23:56 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 777 | $2.48 | $1,926.96 |
DisclosureSEC source: 0001178579-26-000008 · form4-06292026_110657.xml · nonDerivative · entry 6 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,533,845 F7 · price: These shares were purchased in multiple transactions at prices ranging from $2.44 to $2.52. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 580,669 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 29, 2026 Filed Jun 29, 2026 23:56 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 63,985 | $2.47 | $158,042.95 |
DisclosureSEC source: 0001178579-26-000008 · form4-06292026_110657.xml · nonDerivative · entry 5 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,533,068 F6 · price: These shares were purchased in multiple transactions at prices ranging from $2.40 to $2.59. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 580,669 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 23:56 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 134 | $2.54 | $340.36 |
DisclosureSEC source: 0001178579-26-000008 · form4-06292026_110657.xml · nonDerivative · entry 4 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,469,083 F5 · price: These shares were purchased in multiple transactions at prices ranging from $2.52 to $2.58. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 580,669 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 26, 2026 Filed Jun 29, 2026 23:56 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 75,047 | $2.55 | $191,369.85 |
DisclosureSEC source: 0001178579-26-000008 · form4-06292026_110657.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,468,949 F4 · price: These shares were purchased in multiple transactions at prices ranging from $2.46 to $2.60. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 580,669 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 23:56 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 510 | $2.56 | $1,305.60 |
DisclosureSEC source: 0001178579-26-000008 · form4-06292026_110657.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,393,902 F3 · price: These shares were purchased in multiple transactions at prices ranging from $2.53 to $2.60. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 580,669 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 25, 2026 Filed Jun 29, 2026 23:56 UTC | Boundless Bio, Inc. BOLD · Entity 7063 | PurchaseCommon Stock | 145,880 | $2.48 | $361,782.40 |
DisclosureSEC source: 0001178579-26-000008 · form4-06292026_110657.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 2,393,392 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $2.42 to $2.56. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 7. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 580,669 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 791,839 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 580,668 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 580,669 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 01:54 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | OtherShort Put Options (potential obligation to buy) · Derivative | 10,000 | $1.65 Strike: $15.00 | $16,500.00 |
DisclosureSEC source: 0001178579-26-000004 · form4-06032026_010631.xml · derivative · entry 6 TANG KEVIN · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 10,000 Underlying: Common Shares · 1,000,000 shares Expires 2027-01-15 F7 · derivative.exercise_date: Each put option is exercisable only at the option of the counterparty through the expiration date of the put option. F8 · balance_after: Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027. F8 · ownership.nature: Securities are beneficially held by TCP III and TCP IV. The Funds sold 10,000 put options on June 2, 2026. Pursuant to the put option contracts, the Funds have the potential obligation to acquire 1,000,000 common shares of the Issuer at $15 expiring on January 15, 2027. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 01:54 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 206,005 | $15.28 | $3,147,756.40 |
DisclosureSEC source: 0001178579-26-000004 · form4-06032026_010631.xml · nonDerivative · entry 5 TANG KEVIN · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 13,044,106 F6 · price: These shares were purchased in multiple transactions ranging from $15.00 to $15.40. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 01:54 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 99 | $15.34 | $1,518.66 |
DisclosureSEC source: 0001178579-26-000004 · form4-06032026_010631.xml · nonDerivative · entry 4 TANG KEVIN · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 12,838,101 F5 · price: These shares were purchased at $15.34. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 01:54 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 343,521 | $15.28 | $5,249,000.88 |
DisclosureSEC source: 0001178579-26-000004 · form4-06032026_010631.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 12,838,002 F4 · price: These shares were purchased in multiple transactions ranging from $14.97 to $15.50. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 262,682 | $15.31 | $4,021,661.42 |
DisclosureSEC source: 0001178579-26-000004 · form4-06032026_010631.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 12,494,481 F3 · price: These shares were purchased in multiple transactions ranging from $15.05 to $15.37. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Read SEC document |
| May 29, 2026 Filed Jun 3, 2026 01:54 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 2,299 | $15.35 | $35,289.65 |
DisclosureSEC source: 0001178579-26-000004 · form4-06032026_010631.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · Director · Chief Executive Officer · 10% owner TANG CAPITAL MANAGEMENT LLC · CIK 0001232621 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 12,231,799 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $15.33 to $15.38. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 6. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 7,205,442 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares, Tang Capital Partners III, Inc. ("TCP III") beneficially owns 324,814 shares, and Tang Capital Partners IV, Inc. ("TCP IV") beneficially owns 274,811 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV, which are indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI, TCP III and TCP IV (collectively, the "Funds"). Read SEC document |
| March 03, 2026 Filed Mar 3, 2026 22:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 184,208 | $14.22 | $2,619,437.76 |
DisclosureSEC source: 0001178579-26-000001 · form4-03032026_100309.xml · nonDerivative · entry 6 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 12,229,500 F7 · price: These shares were purchased in multiple transactions ranging from $13.97 to $14.39. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 22:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 115,792 | $14.21 | $1,645,404.32 |
DisclosureSEC source: 0001178579-26-000001 · form4-03032026_100309.xml · nonDerivative · entry 5 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 12,045,292 F6 · price: These shares were purchased in multiple transactions ranging from $14.14 to $14.33. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| March 02, 2026 Filed Mar 3, 2026 22:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 83,561 | $14.33 | $1,197,429.13 |
DisclosureSEC source: 0001178579-26-000001 · form4-03032026_100309.xml · nonDerivative · entry 4 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,929,500 F5 · price: These shares were purchased in multiple transactions ranging from $14.04 to $14.50. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 1,600 | $14.38 | $23,008.00 |
DisclosureSEC source: 0001178579-26-000001 · form4-03032026_100309.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,845,939 F4 · price: These shares were purchased in multiple transactions ranging from $14.35 to $14.61. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 214,839 | $14.12 | $3,033,526.68 |
DisclosureSEC source: 0001178579-26-000001 · form4-03032026_100309.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,844,339 F3 · price: These shares were purchased in multiple transactions ranging from $14.00 to $14.18. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 22:35 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 300,000 | $13.90 | $4,170,000.00 |
DisclosureSEC source: 0001178579-26-000001 · form4-03032026_100309.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,629,500 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $13.51 to $14.23. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1 and 3 through 7. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,990,461 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 5,239,039 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| August 05, 2025 Filed Aug 5, 2025 21:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 200,000 | $11.68 | $2,336,000.00 |
DisclosureSEC source: 0001415889-25-021066 · form4-08052025_090800.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,329,500 F4 · price: These shares were purchased in multiple transactions ranging from $11.49 to $11.80. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,371,711 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| August 04, 2025 Filed Aug 5, 2025 21:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 100,000 | $11.34 | $1,134,000.00 |
DisclosureSEC source: 0001415889-25-021066 · form4-08052025_090800.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,129,500 F3 · price: These shares were purchased in multiple transactions ranging from $11.11 to $11.48. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,371,711 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| August 01, 2025 Filed Aug 5, 2025 21:31 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 1,000,000 | $10.12 | $10,120,000.00 |
DisclosureSEC source: 0001415889-25-021066 · form4-08052025_090800.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 11,029,500 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $9.23 to $10.50. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, 3 and 4. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 6,371,711 shares and Tang Capital Partners International, LP ("TCPI") beneficially owns 4,957,789 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP and TCPI. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 22:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 100,000 | $8.09 | $809,000.00 |
DisclosureSEC source: 0001415889-25-006589 · form4-03042025_100358.xml · nonDerivative · entry 6 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 10,029,500 F7 · price: These shares were purchased in multiple transactions at prices ranging from $8.05 to $8.10. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 5,140,591 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 22:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 500,000 | $7.92 | $3,960,000.00 |
DisclosureSEC source: 0001415889-25-006589 · form4-03042025_100358.xml · nonDerivative · entry 5 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 9,929,500 F6 · price: These shares were purchased in multiple transactions at prices ranging from $7.76 to $8.10. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 5,140,591 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III. Read SEC document |
| March 04, 2025 Filed Mar 4, 2025 22:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 148,038 | $8.00 | $1,184,304.00 |
DisclosureSEC source: 0001415889-25-006589 · form4-03042025_100358.xml · nonDerivative · entry 4 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 9,429,500 F5 · price: These shares were purchased in multiple transactions at prices ranging from $7.82 to $8.10. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 5,140,591 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 351,962 | $8.02 | $2,822,735.24 |
DisclosureSEC source: 0001415889-25-006589 · form4-03042025_100358.xml · nonDerivative · entry 3 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 9,281,462 F4 · price: These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.10. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 5,140,591 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 22:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 100,720 | $7.97 | $802,738.40 |
DisclosureSEC source: 0001415889-25-006589 · form4-03042025_100358.xml · nonDerivative · entry 2 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 8,929,500 F3 · price: These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.05. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 5,140,591 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III. Read SEC document |
| February 28, 2025 Filed Mar 4, 2025 22:03 UTC | Aurinia Pharmaceuticals Inc. AUPH · Entity 4463 | PurchaseCommon Shares | 399,280 | $7.85 | $3,134,348.00 |
DisclosureSEC source: 0001415889-25-006589 · form4-03042025_100358.xml · nonDerivative · entry 1 TANG KEVIN · CIK 0001178579 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By LP Disclosed balance after: 8,828,780 F1 · price: The prices reported are weighted-average prices. These shares were purchased in multiple transactions at prices ranging from $7.47 to $7.95. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the SEC staff, upon request, all information regarding the number of shares purchased at each price within the ranges set forth in Footnotes 1, and 3 through 7. F2 · ownership.nature: Tang Capital Partners, LP ("TCP") beneficially owns 5,140,591 shares, Tang Capital Partners International, LP ("TCPI") beneficially owns 4,388,909 shares and Tang Capital Partners III, Inc. ("TCP III") beneficially owns 500,000 shares. Kevin Tang is the sole manager of Tang Capital Management, LLC, which is the general partner of TCP and TCPI. Kevin Tang is the sole director and Chief Executive Officer of TCP III, which is indirectly wholly owned by TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP, TCPI and TCP III. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.